


INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC25033A	SERIAL NO. 10/689381
			APPLICANT DAVID A. GRIFFITH	
			FILING DATE 10/20/03	GROUP Not Available
			126-133, (2000).	
M			Freedland, C.S., et al., "Effects of SR141716A, a Central Cannabinoid Receptor Antagonist, on Food-maintained Responding," <u>Pharmacol Biochem Behav</u> , 67 , 265-270 (2000).	
M			Lan, R., et al., "Structure-Activity Relationships of Pyrazole Derivatives as Cannabinoid Receptor Antagonists" <u>J. Med. Chem.</u> , 42 , 769-776 (1999).	
M			Pertwee, R.G., "Pharmacology of Cannabinoid Receptor Ligands" <u>Curr Med Chem</u> , 6 , 635-664 (1999).	
M			Basavarajappa, B.S., et al., "Chronic Ethanol Administration Down-regulates Cannabinoid Receptors in Mouse Brain Synaptic Plasma Membrane," <u>Brain Res</u> , 793 , 212-218 (1998).	
M			Thomas, B.F., et al., "Comparative Receptor Binding Analyses of Cannabinoid Agonists and Antagonists," <u>J Pharmacol Exp Therap</u> , 285 , 285-292 (1998).	
M			Colombo, G., et al., "Appetite Suppression and Weight Loss after the Cannabinoid Antagonist SR141716," <u>Life Sci.</u> , 63 , PL113-PL117 (1998);	
M			Simiand, J., et al., "SR141716, a CB1 Cannabinoid Receptor Antagonist, Selectively Reduces Sweet Food Intake in Marmose," <u>Behav. Pharmacol.</u> , 9 , 179-181 (1998).	
M			Chaperon, F., et al., "Involvement of Central Cannabinoid (CB1) Receptors in the Establishment of Place Conditioning in Rats," <u>Psychopharmacology</u> , 135 , 324-332 (1998).	
M			Arnone, M., et al., "Selective Inhibition of Sucrose and Ethanol Intake by SR141716, an Antagonist of Central Cannabinoid (CB1) Receptors," <u>Psychopharmacol</u> , 132 , 104-106 (1997).	
M			Savontaus, E., et al., "Anti-Obesity Effect of MPV-1743 A III, a Novel Imidazoline Derivative, in Genetic Obesity," <u>Eur J Pharmacol</u> , 328 , 207-215 (1997).	
M			Sanudo-Pena, M.C., et al., "Endogenous Cannabinoids as an Aversive or Counter-rewarding System in the Rat," <u>Neurosci Lett</u> , 223 , 125-128 (1997).	
M			Gifford, A.N., et al., "Electrically Evoked Acetylcholine Release from Hippocampal Slices is Inhibited by the Cannabinoid Receptor Agonist, WIN 55212-2 and is Potentiated by the Cannabinoid Antagonist, SR 141716A," <u>J Pharmacol Exp Ther</u> , 277 , 1431-1436 (1996).	
M			Compton, D.R., et al., "In Vivo Characterization of a Specific Cannabinoid Receptor Antagonist (SR141716A); Inhibition of Delta-9-Tetrahydrocannabinol-Induced Responses and Apparent Agonist Activity," <u>J Pharmacol Exp Ther</u> , 277 , 586-594 (1996).	
M			Mansbach, R.S., et al., "Effects of the Cannabinoid CB1 Receptor Antagonist SR141716A on the Behavior of Pigeons and Rats," <u>Psychopharmacology</u> , 124 , 315-322 (1996).	
M			Lichtman, A.H., et al., "Delta-9-Tetrahydrocannabinol Impairs Spatial Memory through a Cannabinoid Receptor Mechanism," <u>Psychopharmacology</u> , 126 , 125-131 (1996).	
M			Perio, A., et al., "Central Mediation of the Cannabinoid Cue: Activity of a Selective CB1 Antagonist, SR141716A," <u>Behavioral Pharmacology</u> , 7 , 65-71 (1996).	
M			Rinaldi-Carmona, M., et al., "Biochemical and Pharmacological Characterization of SR141716A, The First Potent and Selective Brain Cannabinoid Receptor Antagonist," <u>Life Sci</u> , 56 , 1941-1947 (1995).	

Man Ber 11/9/05



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25033A	SERIAL NO. 10/689381
		APPLICANT DAVID A. GRIFFITH	
		FILING DATE 10/20/03	GROUP Not Available
<i>MB</i>		Pertwee, R., et al., "AM630, A Competitive Cannabinoid Receptor Antagonist," <u>Life Sci.</u> 56, 1949-1955 (1995).	
<i>MB</i>		Rinaldi-Carmona, M., et al., "SR141716A, a Patent and Selective Antagonist of the Brain Cannabinoid Receptor," <u>FEBS Letters</u> , 350, 240-244 (1994).	
<i>MB</i>		Dutta, A., et al., "The Synthesis and Pharmacological Evaluation of the Cannabinoid Antagonist SR 141716A", <u>Med. Chem. Rev.</u> 5, 54-62 (1994).	
<i>MB</i>		Drummond, J., et al., "Evaluation and Synthesis of Aminohydroxyisoxazoles and Pyrazoles as Potential Glycine Agonists," <u>J. Med. Chem.</u> 32, 2116-2128 (1989).	
<i>MB</i>		Murray, W., et al., "A Simple Regioselective Synthesis of Ethyl 1,5-Diarylpyrazole-3-carboxylates" <u>J. Heterocyclic Chem.</u> 26, 1389 (1989).	
<i>MB</i>		Dewey, W.L. "Cannabinoid Pharmacology," <u>Pharmacological Reviews</u> , 38(2)m 151-178 (1986).	
<i>MB</i>		Tewari, R.S., et al., "1,3-Dipolar Cycloaddition and Nucleophilic Substitution Reactions of C-Acetyl and C-Ethoxycarbonyl Derivative of Hydrazidoyl Bromides" <u>Tetrahedron</u> , 29(1) 129-136 (1983).	
<i>MB</i>		Birkofer, L. and K. Richtzenhain, "Silyl-Derivate von Pyrazol, Isoxazol und 1,2,3-Triazol" <u>Chem. Ber.</u> 112, 2829-2836 (1979).	
<i>MB</i>		Franke, H. et al., "Polare Cycloadditionen von elektronenreichen Mehrfachbindungssystemen an 1,3,4-oxadiazolium-Salze: Synthese von 3aH-[1,3,4]Oxadiazolo[3,2-a]chinolinen" <u>Chem. Ber.</u> 112, 3623-3636 (1979).	
<i>MB</i>		Sucrow, W., et al., "Bimolekulare Cyclisierung von 2-(1-Methylhydrazino)maleinsäure-dimethylester" <u>Chem. Ber.</u> 112, 1712-1718 (1979).	
EXAMINER		DATE CONSIDERED 11/9/05	
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>			

JUL 30 2004
PENTAGON INFORMATION OFFICE

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

[illegible]


[illegible]

10/20/03

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)									ATTY. DOCKET NO. PC25033A			SERIAL NO. Not Yet Assigned		
									APPLICANT David A. Griffith					
									FILING DATE Herewith			GROUP		
U.S. PATENT DOCUMENTS														
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
MP	US	6	5	7	9	8	6	8	6/17/03	Asano, et al.	514	211.08		
MP	US	6	2	8	4	7	4	8	9/4/01	Dang, et al.	514	81		
MP	US	6	1	6	6	0	1	6	12/26/00	Okamura, et al.	514	246		
MP	US	5	2	5	6	3	9	8	10/26/93	McAfee, et al.	424	9		
MP	US	5	0	5	7	5	1	7	10/15/91	Johnston, et al.	514	254		
MP	US	4	7	2	8	6	4	4	3/1/88	Yuki, et al.	514	212		
MP	US	4	4	5	9	2	9	6	7/10/84	Ancher, et al.	424	244		
MP	US	3	8	5	0	9	1	7	11/26/74	Muller, et al.	260	243		
MP	US	3	4	5	7	2	6	3	7/22/69	Regnier, et al.	260	252		
MP	US	3	0	1	6	3	7	8	1/9/62	Roch, et al.	260	247.5		
FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
MP	EP	1	2	2	1	4	4	4	6/30/00	European	C07D	473/34		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
MP		Halpern, et al., <u>Obesity Reviews</u> , "Treatment of Obesity: An Update On Anti-Obesity Medications", Volume 4, pages 25-42 (2003)												
MP		Chorvat, et al., <u>J. Med. Chem.</u> , "Synthesis, Corticotropin-Releasing Factor Receptor Binding Affinity, and Pharmacokinetic Properties of Triazolo-, Imidazo-, and Pyrrolopyrimidines and -Pyridines", Volume 42, pages 833-848 (1999)												
MP		Legraverend, et al., <u>Bioorganic & Medicinal Chemistry Letters</u> , "Synthesis of C2 Alkynylated Purines, A New Family of Potent Inhibitors of Cyclin-Dependent Kinases", Volume 8, pages 793-798 (1998)												
MP		Camaioni, et al., <u>Bioorganic & Medicinal Chemistry</u> , "New Substituted 9-Alkylpurines as Adenosine Receptor Ligands", Volume 6, pages 523-533 (1998)												
MP		Young, et al., <u>J. Med. Chem.</u> , "Purine Derivatives as Competitive Inhibitors of Human Erythrocyte Membrane Phosphatidylinositol 4-Kinase", Volume 33, pages 2073-2080 (1990)												
MP		Montgomery, et al., <u>Journal of the American Chemical Society</u> , "Synthesis of Potential Anticancer Agents. XXVI. The Alkylation of 6-Chloropurine", Volume 83, pages 630-635 (1960)												

Marek Ueda

11/9/05

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25033A		SERIAL NO. Not Yet Assigned
		APPLICANT David A. Griffith		
		FILING DATE Herewith		GROUP
MB		Koppel, et al., <u>Journal of Organic Chemistry</u> , "Potential Purine Antagonists. XIII. Synthesis of Some 8-Methylpurines", Volume 23, pages 1457-1460 (October 1958)		
MB		Ding, et al., <u>Tetrahedron Letters</u> , "Expanding the Diversity of Purine Libraries", Volume 42, pages 8751-8755 (2001)		
EXAMINER				DATE CONSIDERED 11/9/05
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

Conforms with FORM PTO-FB-A820


INFORMATION DISCLOSURE



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25033A		SERIAL NO. 10/689381		
		APPLICANT DAVID A. GRIFFITH				
		FILING DATE 10/20/03		GROUP Not Available		
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
MM	US 20030199536 A1	10/23/03	Thomas, et al.			
MM	US 20030139386 A1	07/24/03	Cote, et al.			
MM	US 20030114495 A1	06/19/03	Finke, et al.			
MM	US 20030055033 A1	03/20/03	Achard, et al.			
MM	US 20030003145 A1	01/02/03	Abramovici, et al.			
MM	US 20020119972 A1	08/29/02	Leftheris, et al.			
MM	US 20020188007 A1	12/12/02	Barth, et al.			
MM	US 20020035102 A1	03/21/02	Achard, et al.			
MM	US 20020019383 A1	02/14/02	Achard, et al.			
MM	US 20010053788 A1	12/20/01	Lange, et al.			
MM	US 20010027193 A1	10/04/01	Achard, et al.			
MM	US 20020128302 A1	09/12/02	Maruani, et al.			
MM	US 2002091114 A1	07/11/02	Plot-Grosjean, et al.			
MM	US 20020091114 A1	07/11/02	Plot-Grosjean, et al.			
MM	US 20020019421 A1	02/14/02	Biberman, et al.			
MM	US 6,566,356 B2	05/20/03	Achard, et al.			
MM	US 6,518,264 B2	02/11/03	Achard, et al.			
MM	US 6,509,367 B1	01/21/03	Martin, et al.			
MM	US 6,479,479 B2	11/12/02	Achard, et al.			
MM	US 6,476,060 B2	11/05/02	Lange, et al.			
MM	US 6,432,984 B1	08/13/02	Barth, et al.			
MM	US 6,355,631 B1	03/12/02	Bouchard, et al.			

Man Bar

11/9/06



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25033A		SERIAL NO. 10/689381		
		APPLICANT. DAVID A. GRIFFITH				
		FILING DATE 10/20/03		GROUP Not Available		
<i>W</i>	US 6,100,259	08/08/00	Xiang, et al.			
<i>W</i>	US 6,028,084	02/22/00	Barth, et al.			
<i>W</i>	US 5,925,768	07/20/99	Barth, et al.			
<i>W</i>	US 5,747,524	05/05/98	Cullinan, et al.			
<i>W</i>	US 5,744,493	04/28/98	Boigegrain, et al.			
<i>W</i>	US 5,744,491	04/28/98	Boigegrain, et al.			
<i>W</i>	US 5,624,941	04/29/97	Barth, et al.			
<i>W</i>	US 5,596,106	01/21/97	Cullinan, et al.			
<i>W</i>	US 5,462,960	10/31/95	Barth, et al.			
<i>W</i>	US 4,925,846	05/15/90	Deacon, et al.			
<i>W</i>	US 5,134,142	07/28/92	Matsuo, et al.			
<i>W</i>	US 4,944,790	07/31/90	Moser, et al.			
<i>W</i>	US 6,344,474 B1	02/05/02	Maruani, et al.			

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
<i>W</i>	WO 03/087037 A1	10/23/03	PCT			
<i>W</i>	WO 03/086288 A2	10/23/03	PCT			
<i>W</i>	WO 03/084943 A2	10/16/03	PCT			
<i>W</i>	WO 03/082833 A1	10/09/03	PCT			X
<i>W</i>	WO 03/082191 A2	10/09/03	PCT			
<i>W</i>	WO 03/082190 A2	10/09/03	PCT			
<i>W</i>	WO 03/078413 A1	09/25/03	PCT			


















Mark Ben


11/9/05



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25033A		SERIAL NO. 10/689381			
		APPLICANT DAVID A. GRIFFITH					
		FILING DATE 10/20/03		GROUP Not Available			
AM	WO 03/077847 A2	09/25/03	PCT				
AM	WO 03/051851 A1	06/26/03	PCT				
AM	WO 03/051850 A1	06/26/03	PCT				
AM	WO 03/040107 A1	05/15/03	PCT				
AM	WO 03/027114 A1	04/03/03	PCT				
AM	WO 03/027076 A2	04/03/03	PCT				
AM	WO 03/027069 A1	04/03/03	PCT				
AM	WO 03/026648 A1	04/03/03	PCT				
AM	WO 03/026647 A1	04/03/03	PCT				
AM	WO 03/020217 A2	03/13/03	PCT				
AM	WO 03/007887 A2	01/30/03	PCT				
AM	WO 03/006007 A1	01/23/03	PCT				
AM	WO 02/076949 A1	10/03/02	PCT				
AM	WO 01/032663 A2	05/10/01	PCT				
AM	WO 01/032629 A1	05/10/01	PCT				
AM	WO 01/029007 A1	04/26/01	PCT				
AM	CA 2,387,138 equiv. to WO 01/028557 A1	04/26/01	CA				
AM	WO 00/15609 A1	05/23/00	PCT				x
AM	WO 96/02248 A1	02/01/96	PCT				
AM	WO 03/027114 A1	04/03/03	PCT				
AM	EP 293,220 B1	8/31/94	EP				
AM	WO 03/082256 A2	10/09/03	PCT				
AM	WO 03/018060 A1	03/06/03	PCT				
AM	WO 01/85092 A2	11/15/01	PCT				

Man Ben 11/09/05

(Use several sheets if necessary)		APPLICANT DAVID A. GRIFFITH					
		FILING DATE 10/20/03		GROUP Not Available			
	WO 01/24798 A1	04/12/01	PCT				
	WO 01/58450 A2	08/16/01	PCT				x
	WO 03/075660 A1	09/18/03	PCT				
	WO 03/020314 A1	03/13/03	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Tzavara, E.T., et al., "The CB1 Receptor Antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: Implications for Therapeutic Actions," <u>J Pharmacol</u> , 138, 544-553 (2003).						
	Racz, I., et al., "A Critical Role for the Cannabinoid CB1 Receptors in Alcohol Dependence and Stress-Stimulated Ethanol Drinking," <u>J Neurosci</u> , 23(6), 2453-2458 (2003).						
	Crocì, T., et al., "Role of Cannabinoid CB1 Receptors and Tumor Necrosis Factor- α in the gut and systemic anti-inflammatory activity of SR 141716 (Rimonabant) in rodents," <u>Brit J Pharmacol</u> , 140, 115-122 (2003).						
	DaSilva, G.E., et al., "Potentiation of Penile Erection and Yawning Responses to Apomorphine by Cannabinoid Receptor Antagonists in Rats," <u>Neurosci Lett</u> , 349, 49-52 (2003).						
	Wang, L., et al., "Endocannabinoid Signaling via Cannabinoid Receptor 1 is Involved in Ethanol Preference and its Age-Dependent Decline in Mice," <u>PNAS</u> , 100(3), 1393-1398 (2003).						
	Ruiu, S., et al., "Synthesis and Characterization of NESS 0327: A Novel Putative Antagonist of the CB1 Cannabinoid Receptor," <u>J Pharmacol Exp Therap</u> , 306, 363-370 (2003).						
	Howlett, A.C., et al., "International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors," <u>Pharmacol Rev</u> , 54, 161-202 (2002).						
	Gomez, R., et al., "A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding," <u>J. Neurosci</u> , 22(21), 9612-9617 (2002).						
	Wiley, J.L., et al., "Novel Pyrazole Cannabinoids: Insights into CB1 Receptor Recognition and Activation," <u>J Pharmacol Exp Therap</u> , 296(3), 1013-1022 (2001).						
	Lellemand, F., et al., "Effects of CB1 Cannabinoid Receptor Blockade on Ethanol Preference After Chronic Ethanol Administration," <u>Alcohol Clin Exp Res</u> , 25(9), 1317-1323 (2001).						
	Pertwee, R.G., "Cannabinoids and the Gastrointestinal Tract," <u>Gut</u> , 48, 859-867 (2001).						
	Pertwee, R.G., "Cannabinoid Receptor Ligands: Clinical and Neuropharmacological Considerations, Relevant to Future Drug Discovery and Development," <u>Exp. Opin. Invest. Drugs</u> , 9(7), 1573-1571 (2000).						
	Hungund, B.L and B.S. Basavarajappa, "Are Anandamide and Cannabinoid Receptors involved in Ethanol Tolerance? A Review of the Evidence," <u>Alcohol & Alcoholism</u> , 35(2)						

 11/9/05